C4 Therapeutics Inc (CCCC)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.76+0.53%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CCCC
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -4.4% |
| Our one-year growth estimate | diamond | -33.3% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 28.9 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
CCCC — CFO transition
Dated 2026-05-15
Chief Accounting Officer — Mark Mossler: Mr. Mossler will no longer serve as the Company’s Chief Accounting Officer.
Why it matters: The presentation may show what cemsidomide can do. This could bring in more investors.
Supportive ifC4 Therapeutics presents a poster at the IMS Annual Meeting from September 23-26, 2026.
Worry ifC4 Therapeutics does not present at the IMS Annual Meeting.
Why it matters: Data from this meeting could show how cemsidomide may work for multiple myeloma.
Watch forGood feedback or results from the biomarker data at the IMS Annual Meeting on September 23-26, 2026.
Also watch forBad feedback or unclear results from the biomarker data at the same meeting.
Why it matters: Progress on the Roche partnership could boost C4's growth and funding plans.
Supportive ifA press release talks about progress with Roche on DACs.
Worry ifNo updates or delays in the Roche partnership progress for over six months.
Why it matters: This trial is key for cemsidomide in treating multiple myeloma.
Supportive ifAn update on dose escalation progress from the Phase 1b trial is provided in the second half of 2026.
Worry ifNo update is given on the trial progress or delays are announced.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$285 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $779 loss on $10,000 · 7.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,210 loss on $10,000 · 52.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Updates on cash will show if the company can fund operations until 2028.
Worry ifConfirmation that cash is enough to fund operations until the end of 2028.
Less concerning ifNews that cash position is getting worse or that more funding is needed.
Why it matters: The presentation will show how well cemsidomide works. It will also cover its safety for multiple myeloma.
Supportive ifThe EHA Congress gave good feedback on cemsidomide's Phase 1 trial results.
Worry ifThere is negative feedback or little interest in the data from the EHA Congress.
Why it matters: Updates on cash will show financial health. This shows the ability to fund operations.
Watch forC4 Therapeutics has over $300 million in cash by Q3 2026.
Also watch forCash position drops below $250 million by Q3 2026.
Why it matters: Completing enrollment is a key step. It helps gather early data on cemsidomide.
Supportive ifEnrollment in the Phase 2 MOMENTUM trial is completed by the end of Q1 2027.
Worry ifEnrollment is delayed beyond the first quarter of 2027.
Why it matters: Updates on the Roche collaboration could show progress in making new cancer therapies. This partnership is key for C4 Therapeutics' growth.
Supportive ifC4 Therapeutics will share more updates from the Roche collaboration by the end of 2026.
Worry ifNo updates or bad news about the Roche collaboration by the end of 2026.
Why it matters: This collaboration may offer important financial help. It can also support C4T's strategy.
Supportive ifC4T gets milestone payments or news on the collaboration's progress.
Worry ifNo financial news or delays in the partnership are reported.
Why it matters: A smooth transition is important. It helps keep investor trust and stability.
Worry ifManagement gave positive comments about the new CFO's plans and vision.
Less concerning ifThere is bad news about the CFO change. This news may cause instability.